Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Pulse Biosciences CS (PLSE)

Pulse Biosciences CS (PLSE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Pulse Biosciences Announces Strategic Alignment to Accelerate Cardiac Catheter Program Following Exceptional Long-Term AFib Clinical Data Business Wire - Tue Mar 17, 6:00AM CDT

Pulse Biosciences, Inc. (Nasdaq: PLSE), pioneer of the novel nPulse™ platform using proprietary Nanosecond Pulsed Field Ablation (nsPFA™), today announced a new strategic alignment to prioritize and...

PLSE : 20.93 (-5.29%)
Pulse Biosciences, Inc. Announces First Enrollments in Feasibility Study for the Treatment of Malignant Thyroid Tumors with nPulse™ Technology Business Wire - Thu Mar 12, 6:00AM CDT

Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced first...

PLSE : 20.93 (-5.29%)
Pulse Biosciences Announces Clinical Data From nPulse™ Vybrance™ System First-In-Human Clinical Durability Study of Benign Thyroid Nodule Ablation Business Wire - Mon Mar 9, 6:00AM CDT

Durable volume reduction was demonstrated with an average volume reduction of 74% of treated benign thyroid nodules at 15-22 months post-treatment.

PLSE : 20.93 (-5.29%)
Pulse Biosciences to Present at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference Business Wire - Thu Mar 5, 6:00AM CST

Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced plans...

PLSE : 20.93 (-5.29%)
Pulse Biosciences’ nPulse™ Vybrance™ System to be Featured in Multiple Presentations at the North American Society for Interventional Thyroidology Meeting Business Wire - Wed Mar 4, 6:00AM CST

nPulse™ Vybrance™ System for soft tissue ablation, such as benign thyroid ablation, to be highlighted in podium presentation and product theatre presentation

PLSE : 20.93 (-5.29%)
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire - Fri Feb 20, 3:05PM CST

Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced that the Compensation...

PLSE : 20.93 (-5.29%)
Pulse Biosciences to Present at the 46th Annual TD Cowen Healthcare Conference Business Wire - Fri Feb 20, 6:00AM CST

Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced plans to present...

PLSE : 20.93 (-5.29%)
Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2025 Financial Results Business Wire - Thu Feb 19, 3:05PM CST

Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced business updates...

PLSE : 20.93 (-5.29%)
Pulse Biosciences Presents Late-Breaking Data from nPulse™ Cardiac Catheter System First-In-Human Feasibility Study at the AF Symposium Business Wire - Thu Feb 5, 6:00PM CST

Procedural success was achieved in 100% of evaluable patients at 6 months and 96% in 12 months

PLSE : 20.93 (-5.29%)
Pulse Biosciences Schedules Fourth Quarter & Full Year 2025 Financial Results Conference Call for February 19, 2026 Business Wire - Wed Feb 4, 3:05PM CST

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced...

PLSE : 20.93 (-5.29%)

Barchart Exclusives

Demand Is ‘Off the Charts’: A $1 Trillion Reason to Buy Nvidia Stock Now Barchart - 1 hour ago
Nvidia’s $1 trillion GPU demand outlook shows a powerful AI growth runway that could support further stock upside. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.